Department of Microbiology, Faculty of Medicine, Oita University, Yufu 879-5593, Japan.
Department of Molecular Pathology, Faculty of Medicine, Oita University, Yufu 879-5593, Japan.
Int J Mol Sci. 2024 Jun 28;25(13):7156. doi: 10.3390/ijms25137156.
Diffuse Large B-cell Lymphoma (DLBCL), with its intrinsic genetic and epigenetic heterogeneity, exhibits significantly variable clinical outcomes among patients treated with the current standard regimen. Disulfidptosis, a novel form of regulatory cell death triggered by disulfide stress, is characterized by the collapse of cytoskeleton proteins and F-actin due to intracellular accumulation of disulfides. We investigated the expression variations of disulfidptosis-related genes (DRGs) in DLBCL using two publicly available gene expression datasets. The initial analysis of DRGs in DLBCL (GSE12453) revealed differences in gene expression patterns between various normal B cells and DLBCL. Subsequent analysis (GSE31312) identified DRGs strongly associated with prognostic outcomes, revealing eight characteristic DRGs (, , , , , , , ). Based on these DRGs, DLBCL patients were stratified into three groups, indicating that (1) DRGs can predict prognosis, and (2) DRGs can help identify novel therapeutic candidates. This study underscores the significant role of DRGs in various biological processes within DLBCL. Assessing the risk scores of individual DRGs allows for more precise stratification of prognosis and treatment strategies for DLBCL patients, thereby enhancing the effectiveness of clinical practice.
弥漫性大 B 细胞淋巴瘤 (DLBCL) 具有内在的遗传和表观遗传异质性，在接受当前标准治疗方案的患者中，其临床结局存在显著差异。二硫键程序性细胞死亡是一种新型的调节性细胞死亡形式，由二硫键应激引发，其特征是由于细胞内二硫键的积累，细胞骨架蛋白和 F-肌动蛋白崩溃。我们使用两个公开的基因表达数据集研究了 DLBCL 中二硫键程序性细胞死亡相关基因 (DRG) 的表达变化。对 DLBCL 中 DRG 的初步分析 (GSE12453) 显示了各种正常 B 细胞和 DLBCL 之间基因表达模式的差异。随后的分析 (GSE31312) 确定了与预后结果强烈相关的 DRG，揭示了八个特征性的 DRG (,,,,,,, )。基于这些 DRG，将 DLBCL 患者分为三组，表明 (1) DRG 可以预测预后，(2) DRG 可以帮助识别新的治疗候选物。这项研究强调了 DRG 在 DLBCL 内各种生物学过程中的重要作用。评估个体 DRG 的风险评分可以更精确地对 DLBCL 患者进行预后和治疗策略分层，从而提高临床实践的效果。
